专题:Metabolism, Diabetes, and Cancer

This cluster of papers explores the role of AMP-activated protein kinase (AMPK) in regulating cellular metabolism, including its involvement in glucose and lipid metabolism, insulin signaling, mitochondrial homeostasis, and the potential impact on cancer risk. The cluster also delves into the mechanisms of action of metformin, a drug known to activate AMPK and its effects on cellular energy balance and gene expression regulation.
最新文献
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

article Full Text OpenAlex

Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6

article Full Text OpenAlex

Chemoproteomic Profiling of Signaling Metabolite Fructose-1,6-Bisphosphate Interacting Proteins in Living Cells

article Full Text OpenAlex

Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

review Full Text OpenAlex

Shear Stress-Induced AMP-Activated Protein Kinase Modulation in Endothelial Cells: Its Role in Metabolic Adaptions and Cardiovascular Disease

article Full Text OpenAlex

GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes

review Full Text OpenAlex

New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions

article Full Text OpenAlex

Metformin for preventing the progression of chronic kidney disease

review Full Text OpenAlex

A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.

article Full Text OpenAlex

A high-fat diet induces changes in mesenteric adipose tissue accelerating early-stage pancreatic carcinogenesis in mice

article Full Text OpenAlex

近5年高被引文献
Once-Weekly Semaglutide in Adults with Overweight or Obesity

article Full Text OpenAlex 3574 FWCI446.71051198

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

article Full Text OpenAlex 1860 FWCI624.65538835

Cancer metabolism: looking forward

review Full Text OpenAlex 1648 FWCI137.19635666

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

article Full Text OpenAlex 1528 FWCI200.39529634

The hallmarks of cancer metabolism: Still emerging

review Full Text OpenAlex 1164 FWCI162.60399299

The cancer metabolic reprogramming and immune response

review Full Text OpenAlex 1124 FWCI88.08326401

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

article Full Text OpenAlex 1080 FWCI134.68562103

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

article Full Text OpenAlex 1020 FWCI880.21162842

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

article Full Text OpenAlex 993 FWCI113.72533883

The metabolism of cancer cells during metastasis

review Full Text OpenAlex 891 FWCI79.11478622